BACKGROUND: Hyaluronic acid (HA) has been found to be an important trigger of atherosclerosis. In this study, we investigate the possible association of serum HA with cardiovascular disease risk in a population of low/intermediate risk for cardiovascular events. METHODS: We enrolled 200 subjects with low/intermediate risk for developing cardiovascular disease. High specific C-reactive protein (hsCRP) was used as an indicator of preclinical atherosclerosis. The Framingham score was used to calculate the cardiovascular risk. RESULTS: Participants with dyslipidemia had significantly higher levels of serum HA than those without dyslipidemia (t-test, P = 0.05), higher levels of hsCRP (Kruskal-Wallis test, P = 0.04), and higher cardiovascular risk according to the Framingham score (Kruskal-Wallis test, P = 0.05). Serum HA concentration correlated significantly with the Framingham score for risk for coronary heart disease over the next 10 years (Spearman r = 0.152, P = 0.02). Diabetic volunteers had significantly higher HA than those without diabetes (t-test, P = 0.02). Participants with metabolic syndrome had higher serum HA levels and higher hsCRP (Kruskal-Wallis test, P = 0.01) compared to volunteers without metabolic syndrome (t-test, P = 0.03). CONCLUSIONS: Serum HA should be explored as an early marker of atheromatosis and cardiovascular risk.
BACKGROUND:Hyaluronic acid (HA) has been found to be an important trigger of atherosclerosis. In this study, we investigate the possible association of serum HA with cardiovascular disease risk in a population of low/intermediate risk for cardiovascular events. METHODS: We enrolled 200 subjects with low/intermediate risk for developing cardiovascular disease. High specific C-reactive protein (hsCRP) was used as an indicator of preclinical atherosclerosis. The Framingham score was used to calculate the cardiovascular risk. RESULTS:Participants with dyslipidemia had significantly higher levels of serum HA than those without dyslipidemia (t-test, P = 0.05), higher levels of hsCRP (Kruskal-Wallis test, P = 0.04), and higher cardiovascular risk according to the Framingham score (Kruskal-Wallis test, P = 0.05). Serum HA concentration correlated significantly with the Framingham score for risk for coronary heart disease over the next 10 years (Spearman r = 0.152, P = 0.02). Diabetic volunteers had significantly higher HA than those without diabetes (t-test, P = 0.02). Participants with metabolic syndrome had higher serum HA levels and higher hsCRP (Kruskal-Wallis test, P = 0.01) compared to volunteers without metabolic syndrome (t-test, P = 0.03). CONCLUSIONS: Serum HA should be explored as an early marker of atheromatosis and cardiovascular risk.
Authors: So Jeong Yoon; Yong Hu Fang; Choon Hak Lim; Bum Shik Kim; Ho Sung Son; Yongdoo Park; Kyung Sun Journal: J Biomed Mater Res B Appl Biomater Date: 2009-10 Impact factor: 3.368
Authors: Kristen R Taylor; Janet M Trowbridge; Jennifer A Rudisill; Christian C Termeer; Jan C Simon; Richard L Gallo Journal: J Biol Chem Date: 2004-02-05 Impact factor: 5.157
Authors: Manuela Viola; Barbara Bartolini; Davide Vigetti; Evgenia Karousou; Paola Moretto; Sara Deleonibus; Tatsuya Sawamura; Thomas N Wight; Vincent C Hascall; Giancarlo De Luca; Alberto Passi Journal: J Biol Chem Date: 2013-08-26 Impact factor: 5.157
Authors: Riley A Suhar; Vanessa M Doulames; Yueming Liu; Meghan E Hefferon; Oscar Figueroa; Hana Buabbas; Sarah C Heilshorn Journal: Biomater Sci Date: 2022-05-17 Impact factor: 7.590
Authors: Teresa Infante; Ernesto Forte; Marco Aiello; Marco Salvatore; Carlo Cavaliere Journal: Front Endocrinol (Lausanne) Date: 2017-08-21 Impact factor: 5.555
Authors: Daniel J Gorski; Anne Petz; Christina Reichert; Sören Twarock; Maria Grandoch; Jens W Fischer Journal: Sci Rep Date: 2019-02-12 Impact factor: 4.379
Authors: F A Tobolowsky; N Wada; O Martinez-Maza; L Magpantay; S L Koletar; F J Palella; T T Brown; J E Lake Journal: PLoS One Date: 2018-01-30 Impact factor: 3.240